Navigation Links
Angiotech announces results for the fourth quarter ended December 31, 2007
Date:2/14/2008

ts owned or controlled by third parties; our ability to obtain

rights to technology from licensors; liability for patent claims and

other claims asserted against us; our ability to obtain and enforce

timely patent and other intellectual property protection for our

technology and products; the ability to enter into, and to maintain,

corporate alliances relating to the development and commercialization of

our technology and products; market acceptance of our technology and

products; our ability to successfully manufacture, market and sell our

products; the ability of Boston Scientific Corporation to successfully

manufacture, market and sell their paclitaxel-eluting coronary stent

products; the continued availability of capital to finance our

activities; our ability to achieve the financial benefits expected as a

result of the acquisition of American Medical Instruments Holdings, Inc.

("AMI"); and any other factors referenced in our annual information form

and other filings with the applicable Canadian securities regulatory

authorities or the SEC. Given these uncertainties, assumptions and risk

factors, readers are cautioned not to place undue reliance on such

forward-looking statements. We disclaim any obligation to update any such

factors or to publicly announce the result of any revisions to any of the

forward-looking statements contained in this press release to reflect

future results, events or developments.

Quill(TM) is a trademark of Quill Medical, Inc., a wholly-owned

subsidiary of Angiotech Pharmaceuticals, Inc.

(C)2008 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

Vascular Wrap(TM) is a trademark of Angiotech Pharmaceuticals, Inc.

BioPince(TM) is a trademark of Medical Device Technologies, Inc.

Skater(TM) is a trademark of PBN MEDICALS DENMARK A/S.

MultiStem(R) is a registered trademark of At
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email: